Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA?

Which outsourcing facilities list compounded semaglutide with FDA?

FDA’s compounded drugs NDC file (dated Sep 18, 2026, read Nov 15, 2026) lists 38 compounded semaglutide products from 15 outsourcing facilities: Apollo Care, LLC (6), Tailstorm Health INC (5), BPI Labs LLC (4), ANNOVEX PHARMA, INC. (3), OurPharma LLC (3), PQ Pharmacy LLC (3), Eagle Pharma Outsourcing, LLC (2), Empower Pharma (2), Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories (2), Hybrid Pharma (2), Turbare Manufacturing (2), Delta Pharma INC (1), MedisourceRx (1), Signature Rx (1) and Wells Pharma of Houston (1). It also lists 33 tirzepatide products from 10 facilities and 4 liraglutide products; every one carries FDA’s category “OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)”.

FDA on this file: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” and “The NDC Directory contains compounded drug products reported and the assigned NDC within the last two years.” The reporting periods in the file run from 2024-2 to 2026-1, as FDA writes them. A product listed here was reported by the facility; the file does not say how much it made, who it sold to, or whether it still makes it.

FDA’s own words on the NDC Directory page (content current as of Mar 4, 2026):

Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved. The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file. Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law. Inclusion in the NDC Directory or assignment of an NDC number does not mean a product is a drug as defined by federal law.

Outsourcing facilities listing compounded GLP-1 products

Each name links to the facility’s page here (matched by exact name) where one exists.

BPI Labs LLC491142024-2, 2025-1, 2025-2, 2026-1
Tailstorm Health INC560112024-2, 2025-1
Apollo Care, LLC62082024-2, 2025-2, 2026-1
PQ Pharmacy LLC32272024-2, 2025-1, 2025-2
ANNOVEX PHARMA, INC.32052025-1
Apothecary Pharma LLC05052026-1
Empower Pharma22042025-1
Hybrid Pharma22042024-2, 2025-1, 2025-2, 2026-1
OurPharma LLC30032024-2, 2025-1
AnazaoHealth Corporation02022025-1
Eagle Pharma Outsourcing, LLC20022025-1
Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB Laboratories20022024-2, 2025-1
Turbare Manufacturing20022025-1
Delta Pharma INC10012025-1
MedisourceRx10012024-2, 2025-1
Olympia Pharmacy00112026-1
PGRrx LLC01012026-1
Signature Rx10012025-1
Wells Pharma of Houston10012025-1

Every compounded GLP-1 listing

Reporting periods
54288-846BPI Labs LLCLiraglutide Injection, 18 mg/3 mL (6 mg/mL)Liraglutide Injection, 18 mg/3 mL (6 mg/mL)INJECTIONSUBCUTANEOUS18 mg/3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
73198-151Olympia PharmacyLiraglutide 6 mg/mLLiraglutide 6mg/mLINJECTION, SOLUTIONSUBCUTANEOUS6 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
81375-606PQ Pharmacy LLCLiraglutideLiraglutideINJECTIONSUBCUTANEOUS6 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2
81375-614PQ Pharmacy LLCLiraglutideLiraglutideINJECTIONSUBCUTANEOUS15 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2
82396-300ANNOVEX PHARMA, INC.SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
82396-302ANNOVEX PHARMA, INC.SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
82396-305ANNOVEX PHARMA, INC.SemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
71170-495Apollo Care, LLCSemaglutide 12.5 mgSemaglutide 12.5 mgINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1
71170-640Apollo Care, LLCSemaglutide 1mg and Cyanocobalamin 0.5mgSemaglutide 1mg and Cyanocobalamin 0.5mgINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2
71170-650Apollo Care, LLCSemaglutide 2.5mg and Cyanocobalamin 0.5mgSemaglutide 2.5mg and Cyanocobalamin 0.5mgINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2
71170-690Apollo Care, LLCSemaglutide 12.5mg and Cyanocobalamin 2.5mgSemaglutide 12.5mg and Cyanocobalamin 2.5mgINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2
71170-811Apollo Care, LLCSemaglutide 2.25 mgSemaglutide 2.25 mgINJECTION, SOLUTIONSUBCUTANEOUS.9 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1
71170-821Apollo Care, LLCSemaglutide 6.75 mgSemaglutide 6.75 mgINJECTION, SOLUTIONSUBCUTANEOUS4.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1
54288-826BPI Labs LLCSemaglutide Injection, 1 mg/mLSemaglutide Injection, 1 mg/mLINJECTIONSUBCUTANEOUS1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
54288-827BPI Labs LLCSemaglutide Injection, 5 mg/2 mL (2.5 mg/mL)Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL)INJECTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
54288-831BPI Labs LLCSemaglutide Injection, 12.5 mg/2.5 mL (5 mg/mL)Semaglutide Injection, 12.5 mg/2.5 mL (5 mg/mL)INJECTIONSUBCUTANEOUS12.5 mg/2.5 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
54288-833BPI Labs LLCSemaglutide Injection, 2.5mg/mL (1mL vial)Semaglutide Injection, 2.5mg/mL (1mL vial)INJECTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
71791-0200Delta Pharma INCSemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
69852-417Eagle Pharma Outsourcing, LLCSemaglutide 1 mg/mLSemaglutide 1 mg/mLINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mgOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
69852-517Eagle Pharma Outsourcing, LLCSemaglutide 2.4 mg/mLSemaglutide 2.4 mg/mLINJECTION, SOLUTIONSUBCUTANEOUS2.4 mg/2.4 mgOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
72627-2321Empower PharmaSemaglutide/CyanocobalaminSemaglutide/CyanocobalaminINJECTIONSUBCUTANEOUS.5 mg/1 mL; 1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
72627-2322Empower PharmaSemaglutide/CyanocobalaminSemaglutide/CyanocobalaminINJECTIONSUBCUTANEOUS5 mg/1 mL; .5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
71266-6100Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB LaboratoriesSemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
71266-6110Fagron Compounding Services LLC dba Fagron Sterile Services LLC dba JCB LaboratoriesSemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
26436-5608Hybrid PharmaSEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1, 2026-1
26436-5635Hybrid PharmaSEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1, 2026-1
70657-1027MedisourceRxSemaglutideSemaglutideSOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
73013-9000OurPharma LLCSemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
73013-9001OurPharma LLCSemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
73013-9002OurPharma LLCSemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
81375-600PQ Pharmacy LLCSemaglutideSemaglutide 2.5mg/mLINJECTION, SOLUTIONSUBCUTANEOUS2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81375-601PQ Pharmacy LLCSemaglutideSemaglutideINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81375-605PQ Pharmacy LLCSemaglutideSemaglutide 5mg/mLINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
84582-4104Signature RxSEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS4 mg/3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
81483-0045Tailstorm Health INCSEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS.25 mg/.05 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0046Tailstorm Health INCSEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS.5 mg/.1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0047Tailstorm Health INCSEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS1 mg/.2 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0048Tailstorm Health INCSEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS1.7 mg/.22 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0049Tailstorm Health INCSEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS2.4 mg/.3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
83556-0201Turbare ManufacturingSemaglutide 1 mg/mLSemaglutide 1 mg/mLINJECTION, SOLUTIONSUBCUTANEOUS1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
83556-0205Turbare ManufacturingSemaglutide 5 mg/mLSemaglutide 5 mg/mLINJECTION, SOLUTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
73702-197Wells Pharma of HoustonSemaglutideSemaglutide injectionINJECTIONINTRAMUSCULAR2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
72682-1205AnazaoHealth CorporationTirzepatide 5mg/mL 2mLTirzepatide 5mg/mL Injection 2mLINJECTIONSUBCUTANEOUS5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
72682-1220AnazaoHealth CorporationTirzepatide 20mg/mL 2mLTirzepatide 20mg/mL 2mLINJECTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
82396-350ANNOVEX PHARMA, INC.TirzepatideTirzepatideINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
82396-351ANNOVEX PHARMA, INC.TirzepatideTirzepatideINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
71170-610Apollo Care, LLCTirzepatide 20mg and Pyridoxine 8mgTirzepatide 20mg and Pyridoxine 8mgINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mL; 4 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2
71170-630Apollo Care, LLCTirzepatide 60mg and Pyridoxine 12mgTirzepatide 60mg and Pyridoxine 12mgINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mL; 4 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2
85091-001Apothecary Pharma LLCTirzepatideTirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS18 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
85091-003Apothecary Pharma LLCTirzepatideTirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS9 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
85091-004Apothecary Pharma LLCTirzepatide and B12Tirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS17 mg/1 mL; 1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
85091-005Apothecary Pharma LLCTirzepatide and B12Tirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS8.5 mg/1 mL; 1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
85091-006Apothecary Pharma LLCTirzepatide and GlycineTirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS17 mg/1 mL; 5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
54288-832BPI Labs LLCTirzepatide Injection, 30 mg/3 mLTirzepatide Injection, 30 mg/3 mLINJECTIONSUBCUTANEOUS10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
54288-835BPI Labs LLCTirzepatide Injection, 10 mg/mLTirzepatide Injection, 10 mg/mLINJECTIONSUBCUTANEOUS10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
54288-836BPI Labs LLCTirzepatide Injection, 60 mg/3 mLTirzepatide Injection, 60 mg/3 mLINJECTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
54288-840BPI Labs LLCTirzepatide and Pyridoxine Hydrochloride Injection, 30 mg/3 mL (10 mg/mL) and 30 mg/3 mL (10 mg/mL)Tirzepatide and Pyridoxine Hydrochloride Injection, 30 mg/3 mL (10 mg/mL) and 30 mg/3 mL (10 mg/mL)INJECTIONSUBCUTANEOUS30 mg/3 mL; 30 mg/3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1
54288-841BPI Labs LLCTirzepatide and Pyridoxine Hydrochloride Injection, 10 mg/mL and 10 mg/mLTirzepatide and Pyridoxine Hydrochloride Injection, 10 mg/mL and 10 mg/mLINJECTIONSUBCUTANEOUS10 mg/1 mL; 10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1
54288-842BPI Labs LLCTirzepatide and Pyridoxine Hydrochloride Injection, 60 mg/3 mL (20 mg/mL) and 30 mg/3 mL (10 mg/mL)Tirzepatide and Pyridoxine Hydrochloride Injection, 60 mg/3 mL (20 mg/mL) and 30 mg/3 mL (10 mg/mL)INJECTIONSUBCUTANEOUS30 mg/3 mL; 60 mg/3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1
54288-848BPI Labs LLCTirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL)Tirzepatide and Pyridoxine Hydrochloride Injection, 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL)INJECTIONSUBCUTANEOUS40 mg/4 mL; 40 mg/4 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-2, 2026-1
54288-859BPI Labs LLCTirzepatide and Pyridoxine Hydrochloride Injection, 20 mg/2 mL (10 mg/mL) and 20 mg/2 mL (10 mg/mL)Tirzepatide and Pyridoxine Hydrochloride Injection, 20 mg/2 mL (10 mg/mL) and 20 mg/2 mL (10 mg/mL)INJECTIONSUBCUTANEOUS20 mg/2 mL; 20 mg/2 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
54288-860BPI Labs LLCTirzepatide and Pyridoxine Hydrochloride Injection, 68 mg/4 mL (17 mg/mL) and 40 mg/4 mL (10 mg/mL)Tirzepatide and Pyridoxine Hydrochloride Injection, 68 mg/4 mL (17 mg/mL) and 40 mg/4 mL (10 mg/mL)INJECTIONSUBCUTANEOUS68 mg/4 mL; 40 mg/4 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
72627-2323Empower PharmaTirzepatide/NiacinamideTirzepatide/NiacinamideINJECTIONSUBCUTANEOUS8 mg/1 mL; 2 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
72627-2324Empower PharmaTirzepatide/NiacinamideTirzepatide/NiacinamideINJECTIONSUBCUTANEOUS2 mg/1 mL; 17 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1
26436-5622Hybrid PharmaTIRZEPATIDE 10MG/MLTIRZEPATIDE 10MG/MLINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1, 2025-2, 2026-1
26436-5636Hybrid PharmaTIRZEPATIDE 20MG/MLTIRZEPATIDE 20MG/MLINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1, 2025-2, 2026-1
85049-420PGRrx LLCTirzepatideTirzepatideINJECTIONSUBCUTANEOUS17 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1
81375-610PQ Pharmacy LLCTirzepatideTirzepatideINJECTION, SOLUTIONSUBCUTANEOUS10 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81375-620PQ Pharmacy LLCTirzepatideTirzepatideINJECTION, SOLUTIONSUBCUTANEOUS20 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0050Tailstorm Health INCTirzepatideTirzepatideINJECTIONSUBCUTANEOUS2.4 mg/.1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0051Tailstorm Health INCTirzepatideTirzepatideINJECTIONSUBCUTANEOUS5 mg/.2 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0052Tailstorm Health INCTirzepatideTirzepatideINJECTIONSUBCUTANEOUS7.5 mg/.3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0053Tailstorm Health INCTirzepatideTirzepatideINJECTIONSUBCUTANEOUS10 mg/.2 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0054Tailstorm Health INCTirzepatideTirzepatideINJECTIONSUBCUTANEOUS12.5 mg/.25 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1
81483-0055Tailstorm Health INCTirzepatideTirzepatideINJECTIONSUBCUTANEOUS15 mg/.3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1

What this file does not show

Only outsourcing facilities that elected to assign NDCs report here, so a facility that compounds a GLP-1 drug without reporting an NDC is not in this file. Every row in the file read carries the outsourcing facility category. FDA’s registered 503B list, inspections and letters for each facility are on its page and on the 503B facilities list.

Common questions

Does an NDC listing mean FDA approved a compounded semaglutide product?

No. FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” The category on these listings is “OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)”.

How often do outsourcing facilities report?

FDA says they report “upon initial registration and in June and December each year” and may update at any time.

Where is the full list of GLP-1 NDC listings?

On the NDC listings page of this site, which also covers bulk ingredient and approved-product listings (467 listings read Nov 15, 2026).

All GLP-1 NDC listings.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.